A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a ...

Several antibody–drug conjugates (ADCs), using ... containing immunochemotherapy regimens in relapsed/refractory B-cell lymphoma and leukemia. Other ADCs directed against other B-cell lineage ...

Takeda's Adcetris has become the first drug recommended for routine NHS use as a treatment for previously untreated ...

Even with significant expansion in the global market for antibodies used in clinical care and research, scientists recognize that there is still untapped potential for finding new antibodies. Many ...

At the beginning of the year Incyte paid $750m to Morphosys for the CD-19 targeting antibody, which has been approved in combination with BMS’ Revlimid (lenalidomide) for adults with relapsed or ...

But the kind involved in this type of lymphoma are B cells. These cells make antibodies, which are proteins that help your body fight germs like bacteria and viruses. Lymphocytes travel around ...

LUND, SE / ACCESS Newswire / March 21, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class ...

The Food and Drug Administration has approved more than 100 monoclonal antibodies to treat a range of diseases. Other ...

Findings on golidocitinib for patients with non-small cell lung cancer whose disease has progressed on anti-PD-1 therapy will be presented this month.

Patients on Adcetris and chemo had better progression-free and overall survival after six years of follow-up compared to those on chemo only.

Chugai introduces Lunsumio for intravenous infusion, a bispecific antibody to treat relapsed or refractory follicular lymphoma in Japan: Tokyo Thursday, March 20, 2025, 11:00 Hrs ...